| Literature DB >> 26939845 |
Abstract
Entities:
Keywords: Bayesian; PARP inhibitor; Phase I; Phase II; Phase III; chemotherapy; randomization; rare cancers; type I error; type II error
Mesh：
Year: 2016 PMID： 26939845 DOI： 10.2217/fon-2016-0033
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404